Erschienen in:
01.07.2015 | Research
The Value of HPV-HR DNA Testing During the Follow-Up After Treatment of CIN3/AIS
verfasst von:
Maja Banović, Vesna Mahovlić, Kristina Meljanac Salopek, Vladimir Banović, Ivan Babić, Slavko Orešković, Damir Babić
Erschienen in:
Pathology & Oncology Research
|
Ausgabe 3/2015
Einloggen, um Zugang zu erhalten
Excerpt
The fact that up to 30 % of women treated for a preinvasive cervical disease are diagnosed with a residual/recurrent disease including an invasive carcinoma during follow-up, requires close surveillance of these patients [
1]. The majority of cases (80–90 %) are detected during the first 2 years after conization [
2]. This in part justifies the anxiety of patients and gynecologists in fearing insufficient treatment or recurrence of the disease and that can lead to over-surveillance and overtreatment. We must keep in mind that these patients are mostly of childbearing age and desire preservation of fertility. Repeated treatments on the cervix can cause negative sequelae in their reproductive health [
3]. …